Tylenol Maker Kenvue Shares Rebound After Trump Links Drug To Autism
Economists saw “limited” risk to the pharmaceutical firm’s stock, despite some expected impact on Tylenol consumption.
Source: MSN The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments